Canaccord Genuity Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Analyst Day Takeaways
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $20.00.
Canaccord analyst, George Farmer, said, "We reiterate our rating on continued positive script trends and aggressive corporate strategy in driving DIFICID adoption as treatment of C. diff infection (CDI)...DIFICID data has been strengthened by multiple independent analyses demonstrating superiority over vancomycin early in treatment course, in patients on concomitant antibiotics, and in lowering recurrence risk. Including activity against toxin and spore production as a plus, the DIFICID value proposition could propel increased front-line use, in our view. Additional strategic priorities to broaden DIFICID use will include initiation of a prophylaxis trial for label expansion, expansion into the Canadian market in H2/12, and exploring potential alliances in new markets."
"Informed by Q4 script trends, a 14- to 28-day wholesale supply target and our view of a fully stuffed channel, we decrease our Q4/11 DIFICID sales estimate to $12.3M from $16.3M, which was overly aggressive. Our $68M 2012 estimate is unchanged. We model for 2014 profitability, consistent with
management guidance, and peak N.A. DIFICID sales of $257M by 2016."
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $12.10 yesterday.
Canaccord analyst, George Farmer, said, "We reiterate our rating on continued positive script trends and aggressive corporate strategy in driving DIFICID adoption as treatment of C. diff infection (CDI)...DIFICID data has been strengthened by multiple independent analyses demonstrating superiority over vancomycin early in treatment course, in patients on concomitant antibiotics, and in lowering recurrence risk. Including activity against toxin and spore production as a plus, the DIFICID value proposition could propel increased front-line use, in our view. Additional strategic priorities to broaden DIFICID use will include initiation of a prophylaxis trial for label expansion, expansion into the Canadian market in H2/12, and exploring potential alliances in new markets."
"Informed by Q4 script trends, a 14- to 28-day wholesale supply target and our view of a fully stuffed channel, we decrease our Q4/11 DIFICID sales estimate to $12.3M from $16.3M, which was overly aggressive. Our $68M 2012 estimate is unchanged. We model for 2014 profitability, consistent with
management guidance, and peak N.A. DIFICID sales of $257M by 2016."
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $12.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Benchmark Reiterates Buy Rating on NVIDIA (NVDA), Updates Estimates
- Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
